Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benvitimod sequential therapy versus calcipotriol sequential therapy for mild to moderate plaque psoriasis in Guangxi
ChiCTR2000032348Phase 4Recruiting
- Sponsor
- Nanning Second People's Hospital
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tapinarof, halometasone and calcipotriol in plaque psoriasis (2 arms), sponsored by Nanning Second People's Hospital. Primary endpoints: Psoriasis Area and Severity Index, Physician's Global Assessment and 2 more. Started Apr 2020; status: recruiting.
02
Drugs
tapinarofhalometasonecalcipotriol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2000032348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032348.